{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001563665","name":"Harvard Apparatus Regenerative Technology, Inc.","summary":"Harvard Apparatus Regenerative Technology (HRGN) is a clinical-stage biotechnology company developing regenerative medicine treatments for gastrointestinal and other organ disorders caused by cancer, trauma, or birth defects. Its lead product, the CellspanTM Esophageal Implant (CEI), uses a patient's own mesenchymal stem cells seeded on a polyurethane scaffold to regenerate damaged esophageal tissue. The company also operates a consumer health products subsidiary in Hong Kong focused on dietary supplements marketed in Asia.","people":[],"products":[{"name":"Cellspan Esophageal Implant (CEI)","type":"hardware","description":"A tubular polyurethane scaffold seeded with a patient's own mesenchymal stem cells to regenerate damaged esophageal tissue, currently in Phase 1 clinical trial."},{"name":"Cellspan Colon Implant","type":"hardware","description":"Pipeline product candidate targeting reconstruction of the colon using the company's organ-regeneration scaffold and stem cell platform."},{"name":"Uterus Wound Repair Product","type":"hardware","description":"Pipeline product candidate for uterus wound repair using the company's regenerative technology platform."},{"name":"Consumer Health Products","type":"service","description":"Dietary supplements and personal healthcare products marketed to consumers in Asia via eCommerce through Hong Kong subsidiary."}],"partnerships":[{"partner_name":"Mayo Clinic","partnership_type":"development","description":"Co-development initiative and clinical trial site for esophageal regeneration; Dr. Dennis Wigle performed first-in-human surgery.","start_date":null},{"partner_name":"University of Michigan Medical Center","partnership_type":"development","description":"Activated clinical trial site for Phase 1 esophageal regeneration trial, began screening patients in Q3 2023.","start_date":null},{"partner_name":"University of Southern California","partnership_type":"development","description":"Clinical trial site activated in Q1 2026 for Phase 1 esophageal regeneration trial.","start_date":null},{"partner_name":"IQVIA","partnership_type":"strategic","description":"Contracted as CRO to manage the company's first Phase 1 clinical trial for esophageal regeneration.","start_date":null},{"partner_name":"Capital Institute of Pediatrics, Beijing","partnership_type":"development","description":"Collaboration with Dr. Lishuang Ma on an Investigator-Initiated Trial for Cellspan esophageal implant in pediatric esophageal atresia patients.","start_date":null},{"partner_name":"University of Texas Medical Branch","partnership_type":"development","description":"FDA-approved clinical-grade human cell culture facility performing cell seeding for esophageal implant manufacturing.","start_date":null},{"partner_name":"Connecticut Children's Medical Center","partnership_type":"development","description":"Co-development initiative partner for organ-regeneration technology.","start_date":null},{"partner_name":"Yale University","partnership_type":"development","description":"Co-development initiative partner for organ-regeneration technology.","start_date":null},{"partner_name":"McGowan Institute for Regenerative Medicine, University of Pittsburgh","partnership_type":"development","description":"Co-development initiative partner for organ-regeneration technology.","start_date":null}],"affiliations":[],"origin":{"leaf":"a3c1474fb07448281afd93b585157b4df74d97fe5ad173910fb7babe5b46b8d2","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"2cadadf40f790ef4ccd5a42e5050419234eb3079cf641deaf320e45743a00760","parent":"a2ead4e7047e8c9518a9d003351e958e27d1a4a07e87e56268b0582de994ccd5","source":"0001437749-26-009079","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":236,"hourly_limit":500,"remaining":264,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}